B
TARA icon

Bailard’s Protara Therapeutics TARA Stock Holding History

Bailard’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97K Sell
18,617
-5,800
-24% -$34.3K ﹤0.01% 727
2025
Q4 		$130K Sell
24,417
-12,252
-33% -$68.1K ﹤0.01% 731
2025
Q3 		$160K Buy
36,669
+6,900
+23% +$22.3K ﹤0.01% 745
2025
Q2 		$90.2K Hold
29,769
– – ﹤0.01% 742
2025
Q1 		$127K Hold
29,769
– – ﹤0.01% 712
2024
Q4 		$157K Buy
+29,769
New +$96.2K ﹤0.01% 704

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bailard's TARA Position: Q1 2026 in Review

Bailard reduced its Protara Therapeutics (TARA) stake by 24% in Q1 2026, selling an estimated $34.3K and leaving 18,617 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #727.

Bailard first reported a position in TARA in Q4 2024 and has held it in 6 quarters since. The position peaked at $160K in Q3 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Bailard held 18,617 shares of Protara Therapeutics worth $97K as of Q1 2026.
  • Bailard sold 5,800 Protara Therapeutics shares in Q1 2026, an estimated $34.3K.
  • Protara Therapeutics made up ﹤0.01% of Bailard's portfolio in Q1 2026, its #727 holding.
  • Bailard first reported a position in Protara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Bailard's Protara Therapeutics position peaked at $160K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.